company background image

CytomX Therapeutics NasdaqGS:CTMX Stock Report

Last Price


Market Cap







15 Aug, 2022


Company Financials +
CTMX fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

CTMX Stock Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.

CytomX Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CytomX Therapeutics
Historical stock prices
Current Share PriceUS$1.73
52 Week HighUS$7.53
52 Week LowUS$1.19
1 Month Change15.33%
3 Month Change-6.99%
1 Year Change-64.03%
3 Year Change-81.90%
5 Year Change-87.55%
Change since IPO-86.59%

Recent News & Updates

Jul 13

CytomX Therapeutics to cut workforce by about 40%

CytomX Therapeutics (NASDAQ:CTMX) on Wednesday announced strategic actions that are expected to extend the company's cash runway into 2025, including a reduction in its workforce by about 40%. CTMX said it would focus its internal efforts on its wholly-owned therapies, including the support of two investigational new drug applications planned for 2023. CytomX (CTMX) also said that it remains committed to its current alliances with AbbVie (ABBV), Amgen (AMGN), Astellas (OTCPK:ALPMY) (OTCPK:ALPMF) and Bristol-Myers Squibb (BMY). CTMX stock earlier closed +1.6% at $1.30.

Shareholder Returns

CTMXUS BiotechsUS Market

Return vs Industry: CTMX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CTMX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is CTMX's price volatile compared to industry and market?
CTMX volatility
CTMX Average Weekly Movement14.6%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CTMX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: CTMX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2008176Sean McCarthy

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

CytomX Therapeutics, Inc. Fundamentals Summary

How do CytomX Therapeutics's earnings and revenue compare to its market cap?
CTMX fundamental statistics
Market CapUS$114.09m
Earnings (TTM)-US$96.88m
Revenue (TTM)US$72.62m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTMX income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$72.62m
Other ExpensesUS$169.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.47
Gross Margin100.00%
Net Profit Margin-133.42%
Debt/Equity Ratio0%

How did CTMX perform over the long term?

See historical performance and comparison